NHS England’s cost-effectiveness watchdog, (NICE), issued a first draft document saying that it di...
Read moreUnderstanding payer value and evidence requirements to secure pricing and reimbursement for a novel ...
Read moreSince 29th July 2016 the NICE appraisal process for oncology indications in England has been modifie...
Read moreWith eight months left before the UK leaves the EU in March 2019, it was hoped that a clear strategy...
Read moreThe government has launched a consultation that outlines the proposed changes to its price controls ...
Read moreIn June 2018, Remap Consulting had the pleasure of attending the annual National Institute of Health...
Read moreAt the current rate, annual deaths due to AMR is expected to reach 10 million by 2050 globally, with...
Read moreThe aim of this study was to determine the impact of delivery device reducing drug wastage.
Read moreDevelopment and implementation of the optimum price submission strategy for a product in the EU.
Read moreTo determine if there is a difference between incremental cost-effectiveness ratios (ICERs) in oncol...
Read more